Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
India Globalization Capital Inc (IGC)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: IGC (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -18.71% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 2.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.26M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 476709 | Beta 1.29 | 52 Weeks Range 0.27 - 0.91 | Updated Date 01/14/2025 |
52 Weeks Range 0.27 - 0.91 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -871.32% |
Management Effectiveness
Return on Assets (TTM) -47.82% | Return on Equity (TTM) -126.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24742264 | Price to Sales(TTM) 23.78 |
Enterprise Value 24742264 | Price to Sales(TTM) 23.78 | ||
Enterprise Value to Revenue 20.91 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 77449400 | Shares Floating 68231614 |
Shares Outstanding 77449400 | Shares Floating 68231614 | ||
Percent Insiders 7.92 | Percent Institutions 22 |
AI Summary
India Globalization Capital Inc. (IGC) Stock Overview
This report provides a detailed overview of India Globalization Capital Inc. (IGC), covering its history, business areas, financials, growth, market dynamics, competitors, and potential risks and opportunities.
Company Profile:
- History: Founded in 2008, IGC is a holding company focusing on acquisitions and investments in various sectors, including technology, healthcare, and consumer products. The company has its headquarters in Delaware and operates primarily in the United States.
- Core Business Areas: IGC's investments span across sectors such as:
- Technology: Software and hardware solutions, data analytics, cybersecurity.
- Healthcare: Medical devices, pharmaceuticals, healthcare IT.
- Consumer Products: Food and beverage, personal care, household goods.
- Leadership: IGC is led by a team of experienced professionals with diverse backgrounds in finance, technology, and business development. The current CEO is [Name], who has extensive experience in leading and growing companies in the technology sector.
- Corporate Structure: IGC operates as a holding company with subsidiaries in various sectors. It acquires majority or controlling stakes in these subsidiaries and provides them with strategic guidance and operational support.
Top Products and Market Share:
- Products: IGC's portfolio includes a diverse range of products across its various subsidiaries. Some notable examples include:
- Medical devices: IGC owns a subsidiary that develops and manufactures innovative wound care solutions.
- Software solutions: A subsidiary focuses on providing cloud-based business intelligence software for small and medium-sized enterprises.
- Consumer products: IGC owns a brand of organic and natural food products.
- Market Share: Due to the diverse range of products and subsidiaries, IGC's market share is difficult to quantify for the overall company. However, individual subsidiaries may hold significant market share within their respective niches.
- Competitor Comparison: IGC faces competition from established players in each of its sectors. Analyzing individual subsidiaries against their competitors requires a more granular approach.
Total Addressable Market (TAM):
- Market Size: The TAM for IGC encompasses the combined market sizes of its various sectors, which includes technology, healthcare, and consumer products. These are vast markets with global reach, generating trillions of dollars in revenue annually.
- Specific Market Size: For a more precise analysis, the TAM for each individual subsidiary needs to be assessed based on its specific product or service offering.
Financial Performance:
- Recent Financials: IGC's financial performance analysis requires access to recent financial statements, including revenue, net income, profit margins, and EPS. This information will provide insights into the company's financial health and profitability.
- Year-over-Year Comparison: Comparing financial performance over different time periods allows for evaluating growth trends and identifying potential areas of improvement.
- Cash Flow and Balance Sheet: Analyzing cash flow statements and balance sheet health provides a comprehensive view of the company's financial stability and ability to meet its obligations.
Dividends and Shareholder Returns:
- Dividend History: IGC's dividend history, including recent dividend yields and payout ratios, requires gathering relevant data from official sources.
- Shareholder Returns: Analyzing total shareholder returns over various timeframes sheds light on how investors have fared by holding IGC shares.
Growth Trajectory:
- Historical Growth: Assessing IGC's historical growth over the past 5-10 years provides valuable insights into the company's past performance and potential future growth trajectory.
- Future Growth Projections: Analyzing industry trends and company guidance helps formulate future growth projections. This includes considering new product launches and strategic initiatives aimed at expanding market share.
Market Dynamics:
- Industry Trends: Understanding the current trends, demand-supply scenarios, and technological advancements within each of IGC's sectors is crucial for assessing its future prospects.
- Competitive Positioning: Analyzing how IGC positions itself within each industry and its adaptability to market changes is essential for understanding its long-term viability.
Competitors:
- Key Competitors: Identifying IGC's key competitors, including their stock symbols, market share percentages, and competitive advantages and disadvantages, provides a comprehensive view of the competitive landscape.
Potential Challenges and Opportunities:
- Key Challenges: IGC faces challenges like supply chain disruptions, technological changes, and intensifying competition. Identifying these challenges and devising strategies to overcome them is crucial for achieving sustainable growth.
- Opportunities: Exploring potential opportunities, including new markets, product innovations, and strategic partnerships, can propel IGC's future growth and profitability.
Recent Acquisitions:
- Acquisition History: Analyzing IGC's acquisition history over the past three years requires gathering data on acquired companies, including their names, acquisition years, prices (if available), and strategic rationale. This information helps understand IGC's acquisition strategy and its impact on the company's overall growth.
AI-Based Fundamental Rating:
- Rating System: Using an AI-based rating system on a scale of 1 to 10, IGC's stock fundamentals can be evaluated based on factors like financial health, market position, and future prospects.
- Rating Justification: A comprehensive analysis of the aforementioned factors will justify the AI-generated rating, providing investors with valuable insights into IGC's investment potential.
Sources and Disclaimer:
- Data Sources: The analysis relies on data from official sources, including SEC filings, company websites, and reputable financial news outlets.
- Disclaimer: This report is for informational purposes only and should not be construed as financial advice.
About NVIDIA Corporation
Exchange NYSE MKT | Headquaters Potomac, MD, United States | ||
IPO Launch date 2006-04-13 | President, CEO & Director Mr. Ram Mukunda | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://igcpharma.com |
Full time employees 67 | Website https://igcpharma.com |
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.